Physician profile
Gary G Graf
NPI 1053482174
$726,228.91
in general payments reported to CMS, 2019-2025
29 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61K · 2022: $186K · 2023: $190K · 2024: $182K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $295K · Honoraria: $89K · Travel and Lodging: $51K · Consulting Fee: $28K · Food and Beverage: $16K · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $295,112.01 |
| Honoraria | $88,700.00 |
| Travel and Lodging | $51,222.98 |
| Consulting Fee | $28,341.43 |
| Food and Beverage | $15,957.95 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $336,903.02 | 2021-2025 | Mounjaro, Zepbound |
| Averitas Pharma INC. | $145,069.98 | 2023-2025 | Qutenza |
| Novo Nordisk INC | $105,420.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $49,844.94 | 2022-2025 | |
| Ascensia Diabetes Care US INC. | $48,657.61 | 2022-2025 | |
| Grt US Holding, INC. | $21,710.62 | 2022 | |
| Senseonics, Incorporated | $8,000.00 | 2024-2025 | Eversense |
| Mannkind Corporation | $2,803.92 | 2023-2025 | V-Go, Afrezza |
| Corcept Therapeutics | $1,884.00 | 2021-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $1,065.09 | 2022-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $805.64 | 2021-2024 | |
| Amgen INC. | $651.80 | 2021-2025 | Tepezza |
| Zealand Pharma US, INC. | $547.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.18 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $424.24 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $338.17 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $254.59 | 2021-2022 | |
| Horizon Therapeutics Plc | $252.70 | 2022-2023 | Tepezza |
| Dexcom, INC. | $243.38 | 2022 | |
| Abbvie INC. | $233.97 | 2021-2023 | |
| Insulet Corporation | $228.44 | 2022-2025 | Omnipod |
| Medtronic, INC. | $97.54 | 2021-2023 | Minimed 780g |
| Esperion Therapeutics, INC. | $92.53 | 2021 | |
| Beta Bionics, INC. | $80.10 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $52.93 | 2021-2022 | |
| Sequel Med Tech, LLC | $26.07 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $25.00 | 2021 | |
| Amarin Pharma, INC. | $18.76 | 2021 | |
| Currax Pharmaceuticals LLC | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Graf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.